Abstracts

CHANGES IN GUT MICROBIOTA PROFILE IN PWHIV WHO SWITCH FROM EFV/FTC/TDF TO BIC/FTC/TAF

Background: Weight gain is often reported when virologically suppressed people living with HIV (PWHIV) switch to integrase inhibitors (INSTI). Reasons linking INSTI to weight gain are unclear and might be attributed to this HIV drug class, to coformulation with tenofovir alafenamide, and/or influenced by medications, lifestyle and environmental factors. One factor that could impact weight…

THE EFFECTS OF CD4+ LYMPHOPENIA ON THE HUMAN SKIN MICROBIOME

Background: The role of specific immune components in maintaining host-microbial homeostasis remains poorly defined. People with HIV (PWH) and Idiopathic CD4 Lymphocytopenia (ICL) patients exhibit low CD4 T cells in distinct clinical contexts providing a unique opportunity to decipher the role of helper CD4 T cells in skin host-microbial interactions. These patients’ increased risk of…

PROTEOMIC ANALYSIS OF TRANSLOCATING BACTERIAL TAXA REVEALS NOVEL THERAPEUTIC TARGET

Background: Microbial translocation contributes to inflammation in HIV-infected humans and has been associated with increased mortality and morbidity in individuals treated with antiretrovirals. Thus, there is interest in understanding the mechanisms underlying microbial translocation. To characterize translocating bacterial populations, we isolated and identified translocating bacteria from chronically SIV-infected macaques and characterized their genomes and proteomes.…

COMMENSAL BACTERIA WITHIN THE FAMILY LACHNOSPIRACEAE ROBUSTLY INHIBIT HIV INFECTION

Background: The microbiota, the vast collection of microorganisms residing in our body, regulates the susceptibility to and severity of various infectious diseases. In HIV infection, HIV-induced dysbiosis of the gut microbiota is well-recognized. However, it is less clear whether the gut microbiota—and which specific microbes and microbial mechanisms—impacts susceptibility to HIV. Methods: To identify bacterial…

COVID-19 BIVALENT BOOSTER EFFECTIVENESS IN PEOPLE WITH AND WITHOUT IMMUNE DYSFUNCTION

Background: Data on the effectiveness of the bivalent booster vaccine against COVID-19 breakthrough infection and severe outcomes is limited. Methods: Using patient-level data from 54 sites in the U.S. National COVID Cohort Collaborative (N3C), we estimated bivalent booster effectiveness against breakthrough infection and outcomes between 09/01/2022 (bivalent vaccine approval date) to 12/15/2022 (most recent data…